IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IOVANCE BIOTHERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.21+0.59 (+4.33%)
Close on Oct 19, 2026
- Market cap
- $6.40M
- P/E (TTM)
- –
- Dividend yield
- –
Iovance Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $6.44B | $164.85M |
| Enterprise Value | $6.14B | $87.06M |
| PS Ratio | 19.81 | 3.60 |
| PB Ratio | 8.75 | 2.03 |
| P/TBV Ratio | 13.63 | 2.31 |
Enterprise value
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| EV / Sales | 18.89 | 2.43 |
Income (trailing twelve months)
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Revenue | $324.97M | $57.94M |
| Gross Profit | $157.29M | $90.47M |
| Operating Income | -$301.31M | -$21.44M |
| Pretax Income | -$293.78M | -$14.45M |
| Net Income | -$289.52M | -$22.46M |
| EBITDA | -$276.26M | -$16.91M |
Margins
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Gross Margin | 48.4% | 52.3% |
| Operating Margin | -92.7% | -44.5% |
| Pretax Margin | -90.4% | -13.0% |
| Profit Margin | -89.1% | -39.2% |
| EBITDA Margin | -85.0% | -31.3% |
| FCF Margin | -91.2% | -8.85% |
Returns
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -40.4% | -53.1% |
| Return on Assets (ROA) | -31.8% | -41.0% |
| Return on Invested Capital (ROIC) | -57.0% | -32.0% |
| Return on Capital Employed (ROCE) | -37.3% | -37.8% |
Growth
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 34.5% | 6.01% |
Balance sheet
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $297.67M | $62.42M |
| Net Cash (Debt) | $297.67M | $15.68M |
| Net Cash Per Share | $0.66 | $0.66 |
| Equity (Book Value) | $736.05M | $48.79M |
| Book Value Per Share | $1.62 | $1.36 |
| Tangible Book Value | $472.15M | $23.06M |
| Working Capital | $357.41M | $75.77M |
Financial position
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.35 | 3.30 |
| Quick Ratio | 3.74 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$264.18M | -$12.35M |
| Capital Expenditures | -$32.21M | -$1.06M |
| Free Cash Flow | -$296.40M | -$20.28M |
| FCF Per Share | -$0.65 | -$0.42 |
Efficiency
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.36 | 0.38 |
| Inventory Turnover | 3.18 | 2.67 |
| Revenue Per Employee | $333.30K | $398.96K |
| Profits Per Employee | -$296.94K | -$703.34K |
| Employee Count | 975 | 74 |
Dividends and yields
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -4.50% | -22.7% |
| FCF Yield | -4.60% | -9.07% |
| Buyback Yield | -4.54% | -0.73% |
| Shareholder Yield | -4.54% | 0.00% |
Shares
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 452,971,000 | 58,179,650 |
| Shares Change (YoY) | 29.6% | 11.1% |
| Shares Change (QoQ) | 3.39% | 0.54% |
| Float | 451,226,000 | 49,173,100 |
| Shares Held by Insiders | 0.39% | 11.6% |
| Shares Held by Institutions | 63.3% | 59.4% |
Taxes
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Income Tax | -$4.26M | $91.50K |
Scores
| Measure | Iovance Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 16.82 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Iovance Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.